Greece: Recommended vaccinations
Back to search
Export to spreadsheet
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 		 Vaccination not funded by the National Health system
 		 Mandatory vaccination
Years
1819364550596064657475≥ 76
Coronavirus disease (COVID-19)1
COVID-196
COVID-196
RSV
RSV7
RSV8
diphtheria
d9
tetanus
TT9
pertussis
acp10
poliomyelitis
IPV9
Haemophilus influenzae type b infection
Hib
hepatitis B
HepB11
pneumococcal disease2
PCV20
PCV20
meningococcal disease3
MCV4/MenB
measles4
MEAS
MEAS12
mumps
MUMPS
MUMPS12
rubella
RUBE
RUBE12
varicella
VAR13
human papillomavirus infection
HPV9 (F/M)14
HPV9 (F/M)15
influenza
IIV3
IIV3/aIIV3/IIV3-HD16
herpes zoster5
ZOS17
ZOS18
hepatitis A
HepA
HepA

Version:


Footnotes:

  1. https://emvolio.gov.gr/
  2. PPSV23 recommended from 2 years of age in at-risk groups
  3. MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB-4C is recommended to healthy infants in two doses at 2 and 4 months of age, with a booster dose at 12-15 months of age. The MenB-4C is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/ethniko-programma-emboliasmwn-epe-paidiwn-kai-efhbwn/13728-tropopoihsh-ethnikoy-programmatos-emboliasmwn-paidiwn-kai-efhbwn-2025-xronodiagramma-kai-systaseis
  4. 21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
  5. for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
  6. 6m-59y high risk groups, 60-74 1 dose, = 75y 2 doses , immunocompromised 2 doses (interval 6 months)
  7. 60-74 high risk groups
  8. All adults older than 75 years of age.
  9. Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y.
  10. Booster dose 18- 25 y with Tdap or Tdap-IPV, followed by Td or Tdap every 10 y. A single dose of Tdap or Tdap-IPV vaccine should be administered in each pregnancy, preferably from 27 to 36 weeks of gestation, as well as to unvaccinated women who have recently given birth, regardless of the interval between previous Tdacp vaccination.
  11. Three doses, high risk groups
  12. For individuals born after 1970 (one or two doses depending on vaccination history and clinical history)
  13. For unvaccinated individuals born after 1990. Two doses recommended to people belonging to specific occupational categories.
  14. Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2025). 2 doses scheme up to 18 years. for specific at-risk groups vaccination can be extended up to 26 years.
  15. Unvaccinated women and men, aged 19-45 years, belonging to high risk groups.
  16. TIV-HD and aTIV recommended in adults aged >= 65 years.
  17. Two doses (RZV vaccine) in immunocompromised.
  18. RZV 2 doses


More information available at:
https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/


Last update : 10 February 2025